News & Updates

Influenza immunization at midlife neither increases nor reduces the risk of Parkinson’s disease (PD), as shown in a study.

The use of dapagliflozin results in a significant improvement in albuminuria and is well tolerated among patients with sickle cell disease (SCD), reports a study presented at ASH 2025. However, a few of them have experienced a complication of urinary tract infections (UTIs).

Among commonly used antiseizure medications (ASMs), topiramate appears to result in weight loss at 6 and 12 months under either initiation and subsequent adherence or initiation-only effects, reports a study. Other ASMs seem to contribute to greater weight change.

New drug applications approved by US FDA as of 16-31 December 2025 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

For Crohn’s disease (CD) patients with suboptimal response to ustekinumab, doubling the dosing frequency from every 8 weeks to every 4 weeks elicited meaningful improvements in objective and patient-reported outcomes, as shown in a small retrospective study.

New drug applications approved by US FDA as of 16-30 November 2025 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

A recent study has observed a very high recurrence rate for cytomegalovirus (CMV) anterior uveitis (AU), but this can be resolved by antiviral therapy.